Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy

American Journal of Pathology

Volumn 163, Issue 4, 2003, Pages 1457-1465

  Pratt, Julian R ^a   Jones, Miriam E ^a   Dong, Jun ^a   Zhou, Wuding ^a   Chowdhury, Paramit ^a   Smith, Richard A G ^b   Sacks, Steven H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b AdProTech plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE OVEREXPRESSION; GRAFT REJECTION; IMMUNE RESPONSE; KIDNEY DONOR; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RAT; REPERFUSION INJURY; REVASCULARIZATION; TISSUE ENGINEERING; TISSUE INJURY;

EID: 0141844659     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63503-1     Document Type: Article

References (40)

1. Baldwin WM, Pruitt SK, Brauer RB, Daha MR, Sanfillipo F: Complement in organ transplantation: contributions to inflammation, injury and rejection. Transplantation 1995, 59:797-802
2. Weisman HF, Bartow T, Leppo MK, Marsh Jr HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151
3. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore Jr FD: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 1992, 149:1723-1728
4. Mulligan MS, Yeh CG, Rudolph AR, Ward PA: Protective effects of soluble CR1 in complement and neutrophil-mediated tissue injury. J Immunol 1992, 148:1479-1486
5. Passwell J, Schreiner GF, Nonaka M, Beuscher HU, Colten HR: Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 1988, 82:1676-1684
6. Pratt JR, Basheer SA, Sacks SH: Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587
7. Pratt JR, Abe K, Miyazaki M, Zhou W, Sacks SH: In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol 2000, 157:825-831
8. McLaren AJ, Jassem W, Gray DWR, Fuggle SV, Welsh KI, Morris PJ: Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999, 13:266
9. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT: Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 1988, 168:1699-1717
10. Makrides SC, Scesney SM, Ford PJ, Evans KS, Carson GR, Marsh Jr HC: Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J Biol Chem 1992, 267:24754-24761
11. Mossakowska D, Dodd I, Pindar W, Smith RAG: Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation. Eur J Immunol 1999, 29:1955-1965
12. Mossakowska D, Smith RAG: Complement receptors and their therapeutic applications. Recombinant Cell Surface Receptors: Focal Point for Therapeutic Intervention. Edited by MJ Browne. Austin, Texas, R. G. Landes Company, 1997 pp 209-220
13. Smith RAG, Dodd I, Mossakowska DEI: Conjugates of Soluble Peptidic Compounds with Membrane-Binding Agents. Geneva Switzerland, Patent Cooperation Treaty International, 1998 publication no. WO 98/02454
14. Smith GP, Smith TAG: Membrane-targeted complement inhibitors. Mol Immunol 2001, 38:249-255
15. Arbuzova A, Murray D, McLaughlin S: MARCKS, membranes, and calmodulin: kinetics of their interaction. Biochim Biophys Acta 1998, 1376:369-379
16. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP: Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000, 43:2590-2597
17. Dodd I, Mossakowska DE, Camilleri P, Haran M, Hensley P, Lawlor EJ, McBay DL, Pindar W, Smith RAG: Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expr Purif 1995, 6:727-736
18. Fabre J, Lim SH, Morris PJ: Renal transplantation in the rat: details of a technique. Aust N Z J Surg 1971, 41:69-75
19. Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH: Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996, 149:2055-2066
20. Smith RAG, Smith GP: Preclinical and clinical progression of a membrane-targeted complement regulator therapeutic. Mol Immunol 2001, 38:122
21. Sheerin NS, Zhou W, Adler S, Sacks SH: TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney Int 1997, 51:703-710
22. Dragun D, Lukitsch I, Tullius SG, Qun Y, Park JK, Schneider W, Luft FC, Haller H: Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat. Kidney Int 1998, 54:2113-2122
23. Wang Y, Pratt JR, Hartley B, Evans B, Zhang L, Sacks SH: Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997, 52:371-377
24. Lu CY, Penfield JG, Kielar ML, Vazquez MA, Jeyarajah DR: Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int 1999, 55:2157-2186
25. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1992, 55:752-756
26. Ojo AO, Wolfe RA, Held FK, Schmonder RL: Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997, 62:968-972
27. Koning OHJ, Ploeg RJ, van Bockel JH, Groenewegen M, van der Woude FJ, Persijn GG, Hermans J: Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997, 63:1620-1628
28. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL: Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplantation 2000, 5:29-35
29. Granger DN: Role of xanthine oxidase and granulocytes in ischaemia-reperfusion injury. Am J Physiol 1988, 255:H479-H485
30. Bonventre JV: Complement and renal ischemia-reperfusion injury. Am J Kidney Dis 2001, 38:430-436
31. Monsinjon T, Richard V, Fontaine M: Complement and its implications in ischemia/reperfusion: strategies to inhibit complement. Fundam Clin Pharmacol 2001, 15:293-306
32. Makrides SC, Nygren PA, Andrews B, Ford PJ, Evans KS, Hayman EG, Adari H, Uhlen M, Toth CA: Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 1996, 277:534-542
33. Mulligan MS, Warner RL, Rittershaus CW, Thomas LJ, Ryan US, Foreman KE, Crouch LD, Till GO, Ward PA: Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewis-x moieties. J Immunol 1999, 162:4952-4959
34. Harris CL, Williams AS, Linton SM, Morgan BP: Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 2002, 129:198-207
35. Park PM, Haas PN, Cunningham JJ, Alexander L, Bao JM, Guthridge D, Kraus M, Holers VM, Quigg RJ: Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol 2001, 12:1383-1390
36. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000, 105:1363-1371
37. Alfani D, Pretagostini R, Bruzzone P, Smits J, Persijn G, Cortesini R: Kidney transplantation from living unrelated donors. Clin Transplants 1998:205-212
38. Matzinger P: Essay 1: the danger model in its historical context. Scand J Immunol 2001, 54:4-9
39. Salvemini D, Cuzzocrea S: Superoxide, superoxide dismutase and ischaemic injury. Curr Opin Investig Drugs 2002, 3:886-895
40. Burne-Tanley MJ, Rabb H: The role of adhesion molecules and T cells in ischaemic renal injury. Curr Opin Nephrol Hypertens 2003, 12:85-90